Related Experiment Video

Updated: Apr 22, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?

Jame Abraham1

  • 1Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Ave, R-35, Cleveland, OH 44195, USA.

Expert Review of Anticancer Therapy
|October 14, 2014
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is crucial for breast cancer treatment. Inhibiting this pathway can overcome resistance to standard therapies and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in breast cancer, driving tumor growth and progression.
  • PI3K pathway activation is a key mechanism underlying resistance to standard breast cancer treatments, including endocrine therapy, HER2-targeted agents, and chemotherapy.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the PI3K pathway in breast cancer.
  • To explore the role of PI3K pathway inhibition in overcoming treatment resistance.
  • To evaluate novel combination strategies involving PI3K pathway inhibitors.

Main Methods:

  • The study focuses on the molecular mechanisms of PI3K pathway activation and its role in breast cancer.
  • Investigational agents targeting the PI3K pathway were assessed for their ability to restore sensitivity to standard therapies.
  • Clinical trials exploring combinations of PI3K pathway inhibitors with endocrine therapy and other targeted agents are discussed.

Main Results:

  • Targeting the PI3K pathway can re-sensitize breast cancer cells to conventional treatments.
  • Inhibition of PI3K pathway activation is central to overcoming therapeutic resistance.
  • Combination of endocrine therapy with PI3K pathway (mTOR) inhibition demonstrates clinical benefit.

Conclusions:

  • The PI3K/AKT/mTOR pathway is a critical therapeutic target in breast cancer.
  • PI3K pathway inhibitors hold promise for overcoming treatment resistance and improving patient outcomes.
  • Novel combination strategies involving PI3K pathway inhibitors are under active clinical investigation for breast cancer treatment.
Keywords:
AKT inhibitorPI3K inhibitorbreast cancercombination therapymTOR inhibitor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.0K